ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial tested a dietary supplement (nicotinamide riboside) as an add-on for pediatric ulcerative colitis with the goal of improving cellular metabolism in the gut lining. Patients and families may be interested because it targeted a non-immunosuppressive metabolic approach and enrolled children.
Clinicians and researchers may note it as an early-stage feasibility study exploring mitochondrial biology in UC.
Who Should Pay Attention
Pediatric patients with ulcerative colitis, parents and caregivers, pediatric gastroenterologists, IBD researchers interested in metabolism/mitochondrial function and supplement-based interventions.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment19 participants
Study statusTerminated
Source depthTrial registry record
What To Know
This ClinicalTrials.gov record describes a terminated randomized, double-blind pilot trial testing daily oral Nicotinamide Riboside (Niagen) versus placebo in pediatric-onset ulcerative colitis.
It aimed to assess feasibility and effects of NAD+ repletion on intestinal epithelial mitochondrial structure/function; planned dosing was weight-based with capsules supplied by ChromaDex. The trial was listed as terminated and planned enrollment was 19 at UPMC Children’s Hospital of Pittsburgh.
Keep In Mind
The record is a trial registry entry (study record) and notes the study status as TERMINATED; this is a protocol/registration entry, not a report of trial results. Nicotinamide riboside was provided by a commercial supplier (ChromaDex).
The registry lists planned outcomes focused on feasibility and enrollment metrics and mechanistic assessments rather than clinical efficacy endpoints.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of Pittsburgh
Trial IDNCT05561738
Study typeInterventional
Trial phaseNA
Enrollment19 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 10, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis (UC)
Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...